High frequency of spontaneous translocations revealed by FISH in cells from patients with the cancer-prone syndromes ataxia telangiectasia and Nijmegen breakage syndromeStumm M.a · Neubauer S.b · Keindorff S.a · Wegner R.-D.c · Wieacker P.a · Sauer R.b
aInstitute of Human Genetics, Otto-von-Guericke University, Magdeburg; bClinic of Radiation Therapy, University Erlangen-Nürnberg, Erlangen-Nürnberg; and cInstitute of Human Genetics, Campus Virchow-Charité, Berlin (Germany)
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
The application of fluorescence in situ hybridization (FISH) using whole-chromosome paints (WCPs) is proving to be a very powerful technique for revealing chromosomal instability that, for the most part, has gone undetected by conventional cytogenetic analysis. We have analyzed the frequency of translocations in lymphocytes and lymphoblastoid cell lines from ataxia telangiectasia (AT) and Nijmegen breakage syndrome (NBS) homozygotes and heterozygotes using a three-color chromosome-painting technique (WCP 1, 2, 4). With this assay we were able to detect an increased frequency of spontaneous translocations in AT homozygotes (median, 18.47 ± 10.82 translocations per 1,000 metaphase cells; 10 patients) and AT heterozygotes (median, 7.87 ± 3.15 translocations per 1,000 cells; 7 patients), in comparison to controls (median, 2.26 ± 1.75 translocations per 1,000 cells; 10 controls). Analysis of NBS homozygotes (median, 19.05 ± 11.27 translocations per 1,000 cells; 5 patients) and NBS heterozygotes (median, 6.93 ± 3.04 translocations per 1,000 cells; 6 patients) also showed an increased frequency of translocations in these patients compared to controls. The presence of such hitherto undetected chromosomal aberrations corroborate previous findings of spontaneous chromosomal instability in AT and NBS patients, as manifested by an increased rate of open breaks and rearrangements involving chromosomes 7 and 14. Moreover, we show that the degree of genomic instability in AT and NBS patients is even higher than previously established and that some AT and NBS heterozygotes evidence spontaneous chromosomal instability as well. These increased levels of nonspecific translocations could be an important risk factor for the development of malignancies in homozygotes and heterozygotes for ATM or NBS1 gene mutations.
© 2001 S. Karger AG, Basel
- Athma P, Rappaport R, Swift M: Molecular genotyping shows that ataxia telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 92:130–134 (1996).
- Bender MA, Rary JM, Kale PP: G2 chromosomal radiosensitivity in ataxia telangiectasia lymphocytes. Mutat Res 152:39–47 (1985).
- Chessa L, Petrinelli P, Antonelli A, Fiorilli M, Elli R, Marucci L, Federico A, Gandini E: Heterogeneity in ataxia telangiectasia: classical phenotype associated with intermediate cellular radiosensitivity. Am J med Genet 42:741–746 (1992).
Cohen MM, Simpson SJ: The use of lymphoblastoid cells in the study of ataxia-telangiectasia, in Bridges BA, Harnden DG (eds): Ataxia Telangiectasia: A Cellular and Molecular Link Between Cancer, Neuropathology, and Immune Deficiency, pp 203–218 (John Wiley & Sons, New York 1982).
- Conley ME, Spinner NB, Emanuel BS, Nowell PC, Nichols WW: A chromosomal breakage syndrome with profound immunodeficiency. Blood 67:1251–1256 (1986).
- Gebhart E, Neubauer S, Schmitt G, Birkenhake S, Dunst J: Use of three colour chromosome in situ suppression technique for the detection of past radiation exposure. Radiat Res 145:47–52 (1996).
Green AJ, Yates JRW, Taylor AMR, Biggs P, McGuire GM, McConville CM, Billing CJ, Barnes ND: Severe microcephaly with normal intellectual development: the Nijmegen breakage syndrome. Archs Dis Child 73:431–434 (1995).
Lavin MF, Shiloh Y: Ataxia-telangiectasia, in Ochs HD, Smith CIE, Puck JM (eds): Immunodeficiency Disorders: A Molecular and Genetic Approach, pp 306–323 (Oxford University Press, Oxford 1999).
Lichter P, Cremer T: Chromosome analysis by non-isotopic in situ hybridization, in Rooney DE, Czepulkowski BH (eds): Human Cytogenetics: A Practical Approach, Vol 1, pp 157–192 (IRL Press, Oxford 1992).
Look AT: Genes altered by chromosomal translocations in leukemia and lymphomas, in Vogelstein B, Kinzler KW (eds): The genetic basis of human cancer, pp 109–141 (McGraw-Hill, New York 1998).
Neubauer S: Detection of radiosensitivity by means of three color FISH, in Rautenstrauss B, Liehr T (eds): FISH-Technologies. Springer Lab Manual (Springer, Heidelberg 2001, in press).
Neubauer S, Gebhart E, Schmitt G, Birkenhake S, Dunst J: Is chromosome in situ suppression (CISS) hybridization suited as a predictive test for intrinsic radiosensitivity in cancer patients? Int J Oncol 8:707–712 (1996).
Neubauer S, Stumm M, Sauer R, Gebhart E: Detektion von Chromosomenaberrationen durch Drei-Farben-Fluoreszenz in situ Hybridisierung in Ataxia telangiectatica Homozygoten und Heterozygoten, in Stuhrmann M, Dörk T, Karstens JH (eds): Ataxia Telangiectatica. Medizinische Genetik Edition, pp 8–10 (Verlag Medizinische Genetik, München 1999).
- Pandita TK, Pathak S, Geard CR: Chromosome end associations, telomeres and telomerase activity in ataxia telangiectasia cells. Cytogenet Cell Genet 71:86–93 (1995).
- Parshad R, Sanford KK, Jones GM, Tarone RE: G2 chromosomal radiosensitivity of ataxia telangiectasia heterozygotes. Cancer Genet Cytogenet 14:163–168 (1985).
- Sanford KK, Parshad R, Price FM, Jones GM, Tarone RE, Eierman L, Hale P, Waldman TA: Enhanced chromatid damage in blood lymphocytes after G2 phase X irradiation, a marker of the ataxia telangiectasia gene. J natl Cancer Inst 82:1050–1054 (1990).
- Schmid W, Jerusalem F: Cytogenetic findings in two brothers with ataxia-telangiectasia (Louis-Bar syndrome). Arch Genet 45:49–52 (1972).
- Scott D, Spreadborough AR, Roberts SA: Radiation induced G2 delay and spontaneous chromosome aberrations in ataxia telangiectasia homozygotes and heterozygotes. Int J radiat Biol 66:157–163 (1994).
- Seemanov E: An increased risk for malignant neoplasms in heterozygotes for a syndrome of microcephaly, normal intelligence, growth retardation, remarkable facies, immunodeficiency and chromosomal instability. Mutat Res 238:321–324 (1990).
Stumm M: Ataxia telangiectasia Varianten: Zytogenetische und molekular-genetische Untersuchungen an Zellen von Patienten mit spontaner Chromosomen-Instabilität. Dissertation, Free University Berlin (1997).
Stumm M, Wegner RD: Zytogenetik der Ataxia telangiectatica und des Nijmegen Breakage Syndroms, in Stuhrmann M, Dörk T, Karstens JH (eds): Ataxia Telangiectatica. Medizinische Genetik Edition, pp 5–7 (Verlag Medizinische Genetik, München 1999).
- Swift M, Chase CL, Morrell D: Cancer predisposition of AT heterozygotes. Cancer Genet Cytogenet 46:21–27 (1990).
- Swift M, Morrell D, Massey RB, Chase CL: Incidence of cancer in 161 families affected by ataxia telangiectasia. N Engl J Med 325:1831–1836 (1991).
- Tchirkov A, Bay JO, Pernin D, Bignon YJ, Rio P, Grancho M, Kwiatkowski F, Giollant M, Malet P, Verrelle P: Detection of heterozygous carriers of the ataxia telangiectasia (ATM) gene by G2 phase chromosomal radiosensitivity of peripheral blood lymphocytes. Hum Genet 101:312–316 (1997).
- Tupler R, Marseglia GL, Stefanini M, Prosperi E, Chessa L, Nardo T, Marchi A, Maraschio P: A variant of the Nijmegen breakage syndrome with unusual cytogenetic features and intermediate cellular radiosensitivity. J med Genet 34:196–202 (1997).
- Waghray M, Gascon GG, Al-Sedairy S, Hannan MA: Cytogenetic investigations in three cell types of a Saudi family with ataxia telangiectasia. Hum Genet 87:285–289 (1991).
- Weeks DE, Patterson MC, Lange K, Andrais B, Davis RC, Yoder F, Gatti RA: Assessment of chronic gamma radiosensitivity as an in vitro assay for heterozygote identification of ataxia telangiectasia. Radiat Res 128:90–99 (1991).
- Weemaes CMR, Hustinx TWJ, Scheres JMJC, van Munster PJJ, Bakkeren JAJM, Taalman RDFM: A new chromosomal instability disorder: the Nijmegen breakage syndrome. Acta paediat scand 70:557–564 (1981).
Wegner RD, Chzernowska K, Sperling K, Stumm M: Ataxia telangiectasia variants (Nijmegen breakage syndrome), in Ochs HD, Smith CIE, Puck JM (eds): Immunodeficiency Disorders: A Molecular and Genetic Approach, pp 324–334 (Oxford University Press, Oxford 1999).
- Wegner RD, Metzger M, Hanefeld F, Jaspers NGJ, Baan C, Magdorf K, Kunze J, Sperling K: A new chromosomal instability disorder confirmed by complementation studies. Clin Genet 33:20–32 (1988).
Wegner RD, Stumm M: Diagnosis of chromosomal instability syndromes, in Wegner RD (ed): Diagnostic Cytogenetics. Springer Lab Manual, pp 251–268 (Springer, Heidelberg 1999).
- West CML, Elyan SAG, Berry P, Cowan R, Scott D: A comparison of the radiosensitivity of lymphocytes from normal donors, cancer patients, individuals with ataxia telangiectasia (AT) and AT heterozygotes. Int J Radiat Biol 68:197–203 (1995).
Wiencke JK, Wara DW, Little JB, Kelsey KT: Heterogeneity in the clastogenic response to X-rays in lymphocytes from ataxia telangiectasia heterozygotes and controls. Cancer Causes Controls 3:237–245 (1992).
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.